retatrutide mechanism triple agonist glp-1 gip glucagon Schematic illustration of monoagonists, dual agonists and retatrutide mechanism triple agonist glp-1

Those who shouldnt take GLP-1 agonists include people who: are pregnant, nursing, or planning to become pregnant have a history of thyroid cancer or pancreatitis are allergic or sensitive to any of the GLP-1 medications have multiple endocrine neoplasia (MEN) syndrome type 2 Weight loss medications are not recommended for people with past or active eating disorders

Once stable, monitoring every three to six months is appropriate, reducing to six-monthly when control is well established

Archives Internationales de Physiologie

April 2017 , Jennifer Jiang, Dr

However, clinicians must remain cautious about side effects, including urinary tract infections, genital mycotic infections, and rare but serious cases of diabetic ketoacidosis